CDK4 and neutropenia: While most of CDK4/6 inhibitors were associated with an increased incidence of hematologic AEs such as neutropenia and leukopenia, our analysis indicates a more varied profile for non-hematologic AEs, such as Abemaciclib showing a notable increase in events like diarrhea (Additional file 1: Table S12).